FI20060003A - A process for preparing dry high-dose granules of mycophenolate mephetil - Google Patents

A process for preparing dry high-dose granules of mycophenolate mephetil Download PDF

Info

Publication number
FI20060003A
FI20060003A FI20060003A FI20060003A FI20060003A FI 20060003 A FI20060003 A FI 20060003A FI 20060003 A FI20060003 A FI 20060003A FI 20060003 A FI20060003 A FI 20060003A FI 20060003 A FI20060003 A FI 20060003A
Authority
FI
Finland
Prior art keywords
mycophenolate
mephetil
dry high
preparing dry
dose
Prior art date
Application number
FI20060003A
Other languages
Finnish (fi)
Swedish (sv)
Other versions
FI117502B (en
Inventor
Deborah M Lingate
Li-Hua Wang-Kessler
Bindu Joshi
Sayee G Hedge
Leo Gu
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of FI20060003A publication Critical patent/FI20060003A/en
Application granted granted Critical
Publication of FI117502B publication Critical patent/FI117502B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
  • Harvesting Machines For Root Crops (AREA)
  • Dental Preparations (AREA)

Abstract

High dose, dry granulations and aqueous oral suspensions of mycophenolate mofetil or mycophenolic acid, containing active compound (7.5-30 %), suspending/viscosity agent, sweetener, flavor, buffer (to a pH of 5-7), and optionally containing flavor enhancer, wetting agent, antimicrobial agent and color.
FI20060003A 1993-10-01 2006-01-02 Process for preparing dry high-dose granules of mycophenolate mofetil FI117502B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13034393A 1993-10-01 1993-10-01
US13034393 1993-10-01
PCT/US1994/010926 WO1995009626A1 (en) 1993-10-01 1994-09-27 Mycophenolate mofetil high dose oral suspensions
US9410926 1994-09-27

Publications (2)

Publication Number Publication Date
FI20060003A true FI20060003A (en) 2006-01-02
FI117502B FI117502B (en) 2006-11-15

Family

ID=22444241

Family Applications (2)

Application Number Title Priority Date Filing Date
FI961466A FI116773B (en) 1993-10-01 1996-04-01 Process for the preparation of high dose oral suspensions of mycophenolate mofetil
FI20060003A FI117502B (en) 1993-10-01 2006-01-02 Process for preparing dry high-dose granules of mycophenolate mofetil

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FI961466A FI116773B (en) 1993-10-01 1996-04-01 Process for the preparation of high dose oral suspensions of mycophenolate mofetil

Country Status (28)

Country Link
US (1) US5688529A (en)
EP (2) EP0721335B1 (en)
JP (1) JP3844491B2 (en)
CN (1) CN1089583C (en)
AT (1) ATE303143T1 (en)
AU (1) AU678303B2 (en)
BR (1) BR9407728A (en)
CZ (2) CZ301771B6 (en)
DE (1) DE69434474T2 (en)
DK (1) DK0721335T3 (en)
ES (1) ES2248793T3 (en)
FI (2) FI116773B (en)
HK (1) HK1012583A1 (en)
HU (1) HU228672B1 (en)
IL (1) IL111116A (en)
LT (1) LT4099B (en)
LV (1) LV11428B (en)
NO (1) NO310673B1 (en)
NZ (1) NZ274678A (en)
PL (1) PL177323B1 (en)
PT (1) PT721335E (en)
RO (1) RO115412B1 (en)
RU (1) RU2150942C1 (en)
SG (1) SG55007A1 (en)
TW (1) TW427914B (en)
UA (1) UA39962C2 (en)
WO (1) WO1995009626A1 (en)
ZA (1) ZA947683B (en)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
US5346703A (en) 1990-08-07 1994-09-13 Mediventures, Inc. Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels
US5843470A (en) 1995-10-06 1998-12-01 Mdv Technologies, Inc. Method and composition for inhibiting post-surgical adhesions
ID18663A (en) 1996-04-12 1998-04-30 Novartis Ag COMPOSITION OF PHARMACEUTICAL PLATED PHARMACEUTICALS
US5759579A (en) * 1996-12-05 1998-06-02 American Home Products Corporation Pharmaceutical suspension systems
WO1999032151A1 (en) * 1997-12-23 1999-07-01 Alliance Pharmaceutical Corporation Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
EP1113794A2 (en) * 1998-09-14 2001-07-11 Vertex Pharmaceuticals Incorporated Methods of treating viral disease
US6410255B1 (en) * 1999-05-05 2002-06-25 Aurora Biosciences Corporation Optical probes and assays
KR100856353B1 (en) 1999-05-14 2008-09-04 니리어스 파마슈티컬즈, 인크. Novel interleukin-1 and tumor necrosis factor-?modulators, syntheses of said modulators and methods of using said modulators
US6726922B1 (en) 1999-06-28 2004-04-27 Minu, L.L.C. Process and composition for temporarily suppressing pain
EP1259608B1 (en) 2000-02-23 2009-08-12 Life Technologies Corporation Modified fluorescent proteins
JP4395549B2 (en) * 2000-11-16 2010-01-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア Marine actinomycete taxa for the discovery of drugs and fermentation products
FR2819721B1 (en) * 2001-01-19 2005-02-04 L M D TREATMENT OF ESCARTS WITH NON-METABOLIZABLE SUGAR AND POLYMERIC ABSORBER
ES2243457T3 (en) * 2001-01-23 2005-12-01 Gador S.A. COMPOSITION THAT INCLUDES BIFOSPHONATES FOR THE PREVENTION AND / OR TREATMENT OF METABOLIC BONE DISORDERS, PROCEDURE OF PREPARATION OF SUCH COMPOSITION AND USES OF THE SAME.
ATE329578T1 (en) * 2001-02-14 2006-07-15 Forte Iq B V PHARMACEUTICAL COMPOSITION CONTAINING XANTHANG GUM
PT1275377E (en) 2001-07-11 2003-11-28 Fidia Farmaceutici GRANULATES CONTAINING LIPOSOLUVABLE SUBSTANCES AND THEIR PREPARATION
US20040186158A1 (en) * 2001-10-02 2004-09-23 Oh Choon K. Novel composition of carvedilol
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
US7176232B2 (en) * 2002-06-24 2007-02-13 The Regents Of The University Of California Salinosporamides and methods for use thereof
WO2004012746A2 (en) * 2002-08-02 2004-02-12 The Regents Of The University Of California New uses for inhibitors of inosine monophosphate dehydrogenase
US7112581B2 (en) * 2002-09-27 2006-09-26 Nereus Pharmaceuticals, Inc. Macrocyclic lactams
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
CN1823070A (en) * 2003-06-20 2006-08-23 加利福尼亚大学董事会 Salinosporamides and methods for use thereof
CN102151261A (en) * 2003-06-20 2011-08-17 尼瑞斯药品公司 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
WO2005025622A1 (en) * 2003-09-12 2005-03-24 Ryukakusan Co. Ltd. Bitterness-masking particulate jelly beverage
AR045957A1 (en) * 2003-10-03 2005-11-16 Novartis Ag PHARMACEUTICAL COMPOSITION AND COMBINATION
US7087369B2 (en) * 2003-12-17 2006-08-08 The Regents Of The University Of California Cornea preservation medium
BRPI0506535A (en) * 2004-01-23 2007-02-27 Nereus Pharmaceuticals Inc Bisindole pyrroles useful as antimicrobial agents
US7683188B2 (en) * 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
JP2007534697A (en) * 2004-04-27 2007-11-29 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ Process for the preparation of mycophenolate mofetil and other mycophenolate esters
US7579371B2 (en) 2004-04-30 2009-08-25 Nereus Pharmaceuticals, Inc. Methods of using [3.2.0] heterocyclic compounds and analogs thereof
NZ550910A (en) * 2004-04-30 2011-06-30 Nereus Pharmaceuticals Inc [3.2.0] Heterocyclic compounds and methods of using the same
US20050266031A1 (en) 2004-05-25 2005-12-01 Jay Dickerson Pharmaceutical suspension composition
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
US8980930B2 (en) * 2004-06-25 2015-03-17 The Johns Hopkins University Angiogenesis inhibitors
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
US20060051428A1 (en) * 2004-09-03 2006-03-09 Nelson Ayala Aspartame and citrate flavored phosphate salt laxative
US20060093629A1 (en) * 2004-10-29 2006-05-04 Buehler Gail K Dye-free pharmaceutical suspensions and related methods
DK1830838T3 (en) 2004-12-03 2013-01-21 Dana Farber Cancer Inst Inc Compositions and Methods for Treating Neoplastic Diseases
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
WO2007015757A2 (en) 2005-07-21 2007-02-08 Nereus Pharmaceuticals, Inc. Interleukin-1 and tumor necrosis factor-a modulators; syntheses of such modulators and methods of using such modulators
US20070082061A1 (en) * 2005-10-07 2007-04-12 Nelson Ayala Reduction of saltiness with sweeteners
CN101378749A (en) * 2006-02-13 2009-03-04 诺瓦提斯公司 High dosage of mycophenolic acid (MPA)
US7985429B2 (en) 2006-03-03 2011-07-26 C. B. Fleet Company, Inc. Flavored colonic cleansing system
GB0612809D0 (en) * 2006-06-28 2006-08-09 Univ Sunderland Formulation
US7998510B2 (en) * 2006-08-17 2011-08-16 C. B. Fleet Company, Inc. Low dose colonic cleansing system
FR2911506B1 (en) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION IN THE FORM OF STABILIZED AQUEOUS SUSPENSIONS
US7824698B2 (en) * 2007-02-02 2010-11-02 Nereus Pharmaceuticals, Inc. Lyophilized formulations of Salinosporamide A
US8999395B2 (en) * 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
US20090017167A1 (en) * 2007-07-11 2009-01-15 Herbalife International Inc. Mixture and beverage made therefrom for protecting cellular hydration
JP5249941B2 (en) * 2007-10-12 2013-07-31 株式会社龍角散 Granular jelly drink for medicine and method for producing the same
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
US8394816B2 (en) * 2007-12-07 2013-03-12 Irene Ghobrial Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia
US7910616B2 (en) * 2008-05-12 2011-03-22 Nereus Pharmaceuticals, Inc. Proteasome inhibitors
EP2310008A4 (en) * 2008-07-09 2014-03-05 Aspreva Internat Ltd Ph specific solutions of sodium mycophenolic acid for the treatment of eye disorders
CN101671706B (en) * 2009-09-05 2013-09-18 山东新时代药业有限公司 Carbohydrate supplementing method in fermentation process of mycophenolic acid
JP2013504569A (en) * 2009-09-10 2013-02-07 バイアル−ポルテラ アンド シーエー，エス．エー． Oral suspension formulation of eslicarbazepine acetate
US20130005722A1 (en) * 2010-03-23 2013-01-03 Manoj Senapati Pharmaceutical Composition of Mycophenolate Mofetil and Process for Preparing Thereof
NZ723459A (en) 2013-03-14 2017-12-22 Alkermes Pharma Ireland Ltd Prodrugs of fumarates and their use in treating various diseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US9168246B2 (en) 2013-06-27 2015-10-27 Veloxis Pharmaceutical A/S Regimen for suppressing organ rejection
CA2940845C (en) 2014-02-24 2019-09-24 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
WO2016036674A1 (en) 2014-09-02 2016-03-10 Bhupinder Singh Deuterated or a non-deuterated molecule and pharmaceutical formulations
IL251588B1 (en) 2014-10-08 2024-05-01 Pacific Northwest Res Institute Methods and compositions for increasing the potency of antifungal agents
ES2973279T3 (en) * 2014-10-24 2024-06-19 Launxp Biomedical Co Ltd Uses of duloxetine·HCl medication in the preparation of a pharmaceutical composition for the treatment of cancer
US10603299B2 (en) 2016-06-02 2020-03-31 Steven Baranowitz Prevention and treatment of viral infections
WO2017210262A1 (en) 2016-06-02 2017-12-07 Steven Baranowitz Prevention and treatment of viral infections
WO2018167628A1 (en) * 2017-03-13 2018-09-20 Ftf Pharma Private Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
WO2019191119A1 (en) 2018-03-28 2019-10-03 Herbalife International Of America, Inc. Acetylation of polysaccharides
WO2020039263A2 (en) 2018-08-18 2020-02-27 Ftf Pharma Private Limited Pharmaceutical suspension for oral dosage
CN112315962B (en) * 2020-11-17 2022-03-29 北京化工大学 Application of mycophenolic acid in treating and preventing coxsackie virus infection
CN117883379A (en) * 2021-02-12 2024-04-16 浙江贝灵生物医药有限公司 Oral alkaline solvent composition and preparation method and application thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
ZA717826B (en) * 1970-11-27 1973-06-27 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
CH653550A5 (en) * 1981-10-20 1986-01-15 Sandoz Ag PHARMACEUTICAL COMPOSITION FOR DELAYED RELEASE OF A MEDICINE IN THE ORAL AREA.
US4727069A (en) 1987-01-30 1988-02-23 Syntex (U.S.A.) Inc. Heterocyclic aminoalkyl esters of mycophenolic acid, derivatives thereof and pharmaceutical compositions
US4753935A (en) * 1987-01-30 1988-06-28 Syntex (U.S.A.) Inc. Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions
CA2088492A1 (en) * 1990-08-10 1992-02-11 Anormed Inc. Immunosuppressive compositions
US5247083A (en) 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid

Also Published As

Publication number Publication date
ES2248793T3 (en) 2006-03-16
DK0721335T3 (en) 2006-01-09
HU228672B1 (en) 2013-05-28
DE69434474T2 (en) 2006-05-18
EP0721335A1 (en) 1996-07-17
BR9407728A (en) 1997-02-12
ATE303143T1 (en) 2005-09-15
JP3844491B2 (en) 2006-11-15
EP1475091A1 (en) 2004-11-10
HK1012583A1 (en) 1999-08-06
UA39962C2 (en) 2001-07-16
DE69434474D1 (en) 2005-10-06
NO961325L (en) 1996-04-01
ZA947683B (en) 1996-04-01
HUT73675A (en) 1996-09-30
SG55007A1 (en) 1998-12-21
CZ291231B6 (en) 2003-01-15
PL177323B1 (en) 1999-10-29
CZ301771B6 (en) 2010-06-16
JPH09509648A (en) 1997-09-30
LT96039A (en) 1996-10-25
NZ274678A (en) 1999-07-29
PL313772A1 (en) 1996-07-22
FI961466A0 (en) 1996-04-01
CZ95496A3 (en) 1996-06-12
LV11428A (en) 1996-08-20
CN1089583C (en) 2002-08-28
LT4099B (en) 1997-01-27
IL111116A0 (en) 1994-11-28
NO310673B1 (en) 2001-08-13
LV11428B (en) 1996-12-20
FI117502B (en) 2006-11-15
HU9600838D0 (en) 1996-05-28
RU2150942C1 (en) 2000-06-20
FI116773B (en) 2006-02-28
NO961325D0 (en) 1996-04-01
US5688529A (en) 1997-11-18
WO1995009626A1 (en) 1995-04-13
CN1132479A (en) 1996-10-02
AU7920594A (en) 1995-05-01
RO115412B1 (en) 2000-02-28
FI961466A (en) 1996-04-01
EP0721335B1 (en) 2005-08-31
AU678303B2 (en) 1997-05-22
PT721335E (en) 2005-11-30
IL111116A (en) 1998-04-05
TW427914B (en) 2001-04-01

Similar Documents

Publication Publication Date Title
FI20060003A (en) A process for preparing dry high-dose granules of mycophenolate mephetil
NZ234143A (en) Aqueous pharmaceutical suspension formulation for administering substantially insoluble pharmaceutical agents
HK1001834A1 (en) Stable ascorbic acid compositions
IL93817A0 (en) N-(3-hydroxy-4-piperidinyl)-(dihydrobenzofuran,dihydro-2h-benzopyran or dihydro-benzodioxin)carboxamide derivatives,their preparation and pharmaceutical compositions containing them
FI95773B (en) Process for the preparation of an aqueous pharmaceutical composition containing N- (3,4-dimethoxycinnamoyl) anthranilic acid
TNSN93008A1 (en) PROCESS FOR REDUCING THE FORMALDEHYDE CONTENT OF MICROENCAPSULATED FORMULATIONS
CA2172506A1 (en) Mycophenolate mofetil and mycophenolic acid high dose oral suspensions
RU93051781A (en) BETA-PHENYL ISOSERINE- (2R, 3S) AND ITS SALT, METHOD OF ITS PREPARATION AND ITS APPLICATION
FR2742748B1 (en) NOVEL 4-IMIDAZOLIDINONE DERIVATIVE, ITS PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Legal Events

Date Code Title Description
FG Patent granted

Ref document number: 117502

Country of ref document: FI

MA Patent expired